SCHEMBL3607984

SCHEMBL3607984

COCOc1cc(OCc2ccccc2)c(C=O)cc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDCD1 Q15116 1/20 0.51
CD274 Q9NZQ7 1/20 0.51
ERN1 O75460 3/20 0.45
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
CCNB2 O95067 1/20 0.42
CDK1 P06493 1/20 0.42
CDK4 P11802 1/20 0.42
CCNB1 P14635 1/20 0.42
CCND1 P24385 1/20 0.42
CCNB3 Q8WWL7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3613087 0.87 SMN1; SMN2 (0.42) PDCD1CD274ALDH1A1KDM4ECYP1A2
SCHEMBL3603467 0.85 PTPN1 (0.50) ERN1ALDH1A1KDM4ESMN1; SMN2RAB9A
SCHEMBL3605162 0.84 KDM4E (0.44) PDCD1CD274ALDH1A1KDM4ECYP1A2
SCHEMBL2267469 0.82 ERN1 (0.43) PDCD1CD274ERN1ALDH1A1KDM4E
SCHEMBL3608070 0.81 L3MBTL1 (0.45) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL1067302 0.79 ALDH1A1 (0.58) ERN1ALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL3612372 0.79 NPC1 (0.49) PDCD1CD274ERN1ALDH1A1KDM4E
SCHEMBL1963431 0.79 HDAC8 (0.52) ERN1ALDH1A1KDM4ENPC1RAB9A
SCHEMBL1445747 0.79 MAOB (0.50) ERN1ALDH1A1NPC1RAB9AMEN1
SCHEMBL4030463 0.79 TUBB1 (0.53) ERN1ALDH1A1KDM4ESMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016396-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 US disclosed
EP-2128138-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016396-A1 PYRAZOLE COMPOUND SLC5A1, SLC5A2, GLP1R PDCD1 2389/4885CD274 3521/4885ERN1 3332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.